关于PLGA颗粒作为持续药物输送系统及其对视网膜的影响的审查
Sylvana Marquina1, Mustafa Ozgul2, Kenneth Robertson-Brown1
1School of Medicine, University of California Irvine, 843 Health Sciences Road, Irvine, CA, 92697, USA.
Experimental eye research
|August 31, 2023
概括
聚乳糖糖酸 (PLGA) 纳米颗粒为与年龄相关的黄斑变性 (AMD) 提供了有前途的眼内药物输送. 这次审查突出了PLGA的重点.
科学领域:
- 生物材料科学 生物材料科学
- 眼科医生 眼科 眼科
- 药物输送系统 药物输送系统
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是55岁以上人群视力丧失的主要原因,患病率越来越高.
- 目前针对AMD的治疗方法在持续的药物输送和疗效方面面临挑战.
- 聚乳-同-甘油酸 (PLGA) 是FDA批准的,可生物降解和生物相容的聚合物,广泛用于药物输送.
研究的目的:
- 审查与年龄相关的黄斑退行症 (AMD) 治疗的基于聚乳-同-甘油酸 (PLGA) 的药物输送系统的设计和最近的进展.
- 评估PLGA纳米粒子,微粒子和支架在治疗AMD时用于眼内药物输送的潜力.
- 总结了在体外和体内研究中关于PLGA在AMD治疗疗效的证据.
主要方法:
- 对基于PLGA的药物输送系统的现有文献的审查.
- 对研究PLGA颗粒用于AMD治疗的体外和体内研究的分析.
- 在PLGA矩阵中检查各种治疗剂 (,小分子,RNA,蛋白质) 的结合和释放.
主要成果:
- 在形成适合眼内药物给药的纳米粒子,微粒子和支架方面,PLGA表现出了多功能性.
- 基于PLGA的系统显示出持续释放抗血管生成和抗增殖剂的潜力.
- 证据支持PLGA药物载体在AMD临床前模型中的有效性.
结论:
- 基于PLGA的药物递送车辆是长期有效治疗干湿AMD的有希望的策略.
- 生物相容性和生物降解性使PLGA成为眼内治疗的理想候选者.
- 对PLGA配方的进一步研究可以促进与年龄相关的黄斑退行症的治疗.
相关概念视频
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...